How Does Pacira Company Work and Make Money?

How does Company sell non-opioid surgical pain therapies and capture durable revenue?

Company develops long-acting, non-opioid analgesics and delivery tech for hospitals and ambulatory surgery centers. The model earns revenue via product sales, hospital formularies, and reimbursement pathways; in 2025 product mix diversification and higher ASPs drove revenue resilience.

Company monetizes via unit sales, recurring hospital contracts, and lifecycle launches; commercial scale and secured reimbursement improve margin and uptake. See product positioning: Pacira Marketing Mix 4P

Company Name develops non-opioid pain-management products for surgical and musculoskeletal care, led by EXPAREL long-acting bupivacaine and ZILRETTA extended – release steroid injections, plus device-based options for nerve pain control; it sells to hospitals, ambulatory surgery centers (ASCs), and clinics to shorten recovery, lower opioid use, and reduce length of stay.

Core Products and Platforms

Company Name is best known for EXPAREL, a DepoFoam bupivacaine formulation providing up to 96 hours of postsurgical analgesia; ZILRETTA for osteoarthritis knee pain; and minimally invasive device therapies for targeted nerve blocks.

Main Customer Groups

Customers include hospital surgical departments, ASCs, orthopedic and anesthesiology practices, pain clinics, and group purchasing organizations that procure perioperative analgesics and injection therapies.

Commercial Value Delivered

Products reduce opioid prescriptions in the critical 48 – 72 hour window, cut inpatient stays, and support faster functional recovery – metrics that lower total episode costs for payers and improve throughput for ASCs.

Why Providers Choose It

Clinicians favor the predictable multi – day analgesia from EXPAREL and the convenience of single – administration extended – release injections, plus published evidence and hospital protocols that reduce opioid exposure.

Company Name primarily earns revenue through product sales of EXPAREL and ZILRETTA, supported by licensing, royalties, and limited contract – manufacturing income; in 2025 the company reported annual product revenue of $520 million, with EXPAREL representing roughly 65% of product sales, and total 2025 revenue of $557 million.

Core Value Proposition: Opioid – Sparing, Multi – Day Analgesia that Lowers Episode Costs

Company Name sells differentiated, non – opioid analgesics that cover the acute postoperative pain window, generating recurring product revenue from hospitals and ASCs while expanding into outpatient orthopedics.

• EXPAREL long – acting local anesthetic drives the product portfolio
• Primary customers are hospitals, ambulatory surgery centers, and pain/ortho clinics
• Delivers fewer opioids, shorter stays, and faster recovery
• Stands out for DepoFoam sustained release and clinical evidence supporting opioid – sparing pathways

For a focused look at growth initiatives, hospital adoption, and commercial strategy see Growth Strategy and Outlook of Pacira Company

Pacira SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Company Name develops and sells non-opioid analgesics, commercializing its DepoFoam-enabled products through specialized manufacturing and a targeted hospital sales force; in 2025 the business optimized supply chains to meet higher demand after federal reimbursement updates, supporting growth in product revenue and hospital adoption.

Operating model centered on DepoFoam delivery

Company Name's core operating model sells long-acting local analgesics based on its DepoFoam drug-delivery platform, combining proprietary formulation IP with specialty manufacturing and a clinical sales force that integrates products into surgical workflows.

Product and service delivery into surgical settings

Products reach customers via direct hospital and ambulatory surgery center (ASC) sales, distributor partnerships with AmerisourceBergen and Cardinal Health, and in – OR clinical support teams that train surgeons and anesthesiologists on proper use.

Specialized production and R&D

Manufacturing is performed in specialized DepoFoam-capable plants in San Diego and the UK; R&D focuses on formulation improvements and new indications, with research spending affecting margins – Company Name reported R&D investment growth in 2025 to support pipeline expansion.

Sales channels and distribution mix

Sales combine field reps targeting orthopedic surgeons and anesthesiologists, contracts with hospital group purchasing organizations, and wholesalers; ASC penetration rose in 2025 after targeted pricing and reimbursement efforts.

Key assets, systems, and partnerships

Key assets include DepoFoam IP, two specialized manufacturing sites, clinical specialist teams, and distribution agreements; partnerships with major wholesalers and hospital systems stabilize supply and purchasing.

What makes the model work in practice

The combination of hard-to-replicate DepoFoam manufacturing, high-touch clinical support in the OR, and payer-driven reimbursement tailwinds in 2025 created a durable commercial moat that converts product availability into repeat hospital protocol adoption.

Operationally, Company Name runs a production – intensive, clinically integrated commercial engine that converts DepoFoam R&D into recurring product sales and service contracts across hospitals and ASCs.

How Company Name operates in practice

Company Name turns specialized manufacturing and clinical sales into consistent pharmaceutical revenue by aligning production capacity with hospital purchasing and reimbursement trends; Exparel remains the primary revenue driver while licensing and services add incremental income.

• Core model: proprietary DepoFoam platform sells long – acting local analgesics
• Delivery: direct hospital sales plus wholesalers and in – OR clinical support
• Main support: specialized manufacturing sites and distributor partnerships
• Efficiency driver: manufacturing complexity creates barriers and ensures protocolized use

In 2025 Company Name reported approximately $523 million in total revenue, with product sales – led by Exparel – contributing about 90% of revenue; other income from licensing, contract manufacturing, and royalties made up the remainder, while R&D and SG&A pressured operating margins during expansion.

See deeper market targeting and adoption details in this analysis on the company's target market: Target Market of Pacira Company

Pacira PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Company Name primarily makes money by selling high-margin non-opioid analgesic pharmaceuticals, led by EXPAREL sales, plus recurring revenue from ZILRETTA and device/consumable sales; 2025 – 2026 policy and outpatient reimbursement changes amplified demand in ambulatory settings and boosted realized prices and margins.

Main revenue: EXPAREL injectable pain management

EXPAREL drives Company Name revenue, representing about 75 percent of sales as of Q1 2026 and supporting projected full-year revenue near 750 million dollars; hospital and Ambulatory Surgery Center adoption of long-acting bupivacaine underpins unit growth and pricing power.

Additional revenue: ZILRETTA, iovera devices, consumables

ZILRETTA contributes roughly 115 million to 125 million dollars annually from steroid-based chronic pain treatment, while iovera device sales and tips add a smaller but growing revenue stream and recurring consumable income.

Pricing and monetization model: product sales plus reimbursement-driven pricing

Company Name monetizes via direct product sales to hospitals, surgery centers, and distributors, relying on reimbursement (including Medicare changes from January 1, 2025) to support higher net prices and reduce substitution by cheaper opioids.

Primary revenue driver: reimbursement and ambulatory volume

The NOPAIN Act reimbursement shift is the key driver – ambulatory surgery volume growth and separate non-opioid payments increase utilization, while DepoFoam manufacturing scale sustains adjusted EBITDA margins near 30 percent.

Company Name turns clinical adoption into cash by capturing higher ASPs (average selling prices) where reimbursement covers non-opioid options, while product mix shifts toward outpatient settings boost unit sales and margin expansion.

How Company Name monetizes its pain-management portfolio

Company Name converts clinical demand into revenue through high-margin pharmaceutical product sales, supported by reimbursement shifts and scale in manufacturing.

• EXPAREL is the main revenue engine
• ZILRETTA and device consumables are steady secondary streams
• Monetization is product-sales driven with reimbursement-led pricing
• Reimbursement policy and ambulatory surgery adoption drive revenue most

How the Company Makes Money Pacira's revenue model is primarily driven by high-margin product sales, with EXPAREL acting as the dominant engine. As of the first quarter of 2026, EXPAREL continues to account for approximately 75 percent of total revenue, which is projected to hover around 750 million dollars for the full year. The monetization logic changed significantly on January 1, 2025, with the full implementation of the NOPAIN Act. This legislative tailwind provides separate Medicare reimbursement for non-opioid treatments in outpatient settings, effectively removing the cost barrier that previously led hospitals to choose cheaper, generic opioids. This has shifted the growth mix, with Ambulatory Surgery Center volume growing at a double-digit clip. ZILRETTA contributes roughly 115 million to 125 million dollars annually, providing a steady stream of income from the chronic pain market. The company also generates smaller but growing revenue from iovera device sales and consumable tips. Profitability is maintained through disciplined pricing and the realization of economies of scale in their DepoFoam manufacturing lines, leading to adjusted EBITDA margins in the 30 percent range. Competitive Landscape of Pacira Company

Pacira Business Model Canvas

• Complete Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Pacira Company's model rests on premium-priced non-opioid analgesics, a protected drug-delivery platform, and growing med – tech hardware sales; reimbursement rules, hospital protocol adoption, and patent defense sustain margins, while generic entrants, litigation outcomes, and R&D costs threaten revenue and profitability in 2025 – 2026.

Reimbursement and Clinical Adoption Support Revenue

Strong reimbursement under the NOPAIN Act and adoption of EXPAREL in surgical protocols drive hospital purchasing and justify premium pricing, supporting product sales as the primary revenue stream.

Protected Platform and Diversified Commercial Reach

DepoFoam drug – delivery IP and the iovera med – tech hardware plus consumables create multiple revenue channels – drug sales, device sales, and service consumables – backed by established distributor and hospital relationships.

Regulatory, Patent, and Market Concentration Dependencies

Revenue depends on patent protection for EXPAREL, reimbursement policy continuity, and a concentrated hospital customer base; generic entry or adverse litigation outcomes in 2025 would sharply reduce pricing power and sales volume.

Durability Outlook into 2026

Model appears moderately durable near term due to clinical switching costs and NOPAIN-driven reimbursement, but long – term resilience hinges on winning patent suits, expanding iovera, and diversifying beyond EXPAREL before generics emerge.

If litigation or reimbursement shifts, near – term revenue declines could be abrupt given EXPAREL's share of sales; successful iovera scale – up would materially reduce that exposure.

Key Drivers Keeping the Business Model Working

Pacira Company makes money mainly from EXPAREL drug sales, supplemented by iovera device and consumables, licensing, and contract manufacturing; patent protection and reimbursement policy are decisive for valuation in 2025 – 2026.

• Protected DepoFoam platform underpins pricing and product differentiation
• Clinical adoption and reimbursement (NOPAIN Act) enable premium hospital pricing
• High dependency on patent litigation outcomes and limited product portfolio
• Model looks exposed long term unless diversification and legal wins occur

For background on the company's evolution and strategic milestones, see History of Pacira Company

Pacira Marketing Mix

• Covers Marketing Mix Analysis in Details
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔